We are international
• about imf TEXT SIZE   

Dr. Brian G.M. Durie Research Publications Overview

Key publications selected from following Research Publications list.

  1. Durie BGM, Stroud JD, Kahn JA: Progressive systematic sclerosis with malignantatrophic papulosis. Arch Dermatol 100:575, 1969.

  2. Gill W, Carter DC, Durie BGM: Retroperitoneal tumors:A review of 134 cases. JRoyal Coll Surg (Edinburgh), 15:213-221, 1973.

  3. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation ofmeasured myeloma cell mass with presenting clinical features response to treatment and survival. Cancer, 36: 842-854, 1975.

  4. JonesSe, Durie BGM, Salmon SE: Combination chemotherapy with adriamycin andcyclophosphamide for advanced breast cancer.Cancer, 36:90-97, 1975.

  5. Alberts DS, Durie BGM, Salmon SE: Doxorubicin/BCNU chemotherapy for multiple myelomain relapse. Lancet 1:926-928, 1976.

  6. Durie BGM, Salmon SE, Russell DH: Polyamines as makers of response and disease activity in cancer chemotherapy. Cancer Res 37:214-221, 1977.

  7. Durie BGM, Giles HR: Successful treatment of acute leukemia during pregnancy. Arch Int Med 137:90-91, 1977.

  8. Alberts DS, Durie BGM, Salmon SE: Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. CancerTreat Rep 61:381-388, 1977.

  9. Salmon SE, Hamburger AW, Soehnien BS, et al: Quantitation ofdifferential sensitivity of human-tumor stem cells to anticancer drugs. NEngl J Med 298:1321-1327, 1978.

  10. Durie BGM, Salmon SE, Moon TE: Pretreatment tumor mass, cell kinetics and prognosis in multiple myeloma. Blood 55:364-372, 1980.

  11. Woolfenden JM, Platt MJ, Durie BGM, Moon TE: Comparison of bonescintigraphy and radiography in multiple myeloma. Radiology134:723-728, 1980.

  12. Durie BGM, Russell DH, Salmon SE: The plateau phase in multiple myeloma:A reappraisal Lancet 65-68, July, 1980.

  13. Durie BGM, Salmon SE, Mundy GR: Relation of osteoclast activating factor (OAF) production to the extent of bone disease in multiple myeloma. BrJ Haematol47:21-30, 1981.

  14. Durie BGM, Hellman D, O’Mara RE, Woolfenden J, Kartchne tM, Salmon Se: High-risk thyroid cancer. Prolonged survival with early multimodality therapy. Cancer Clin Trials 4:67-73, 1981.

  15. Durie BGM, Cole PW, Chen H-SG, Himmelstein KJ, Salmon SE: Synthesis and metabolism of Bence-Jones protein and calculation of tumor burden in patients with Bence-Jones myeloma. Br J Haematol 47:7-19, 1981.

  16. Hofmann V, Salmon SE, Durie BGM. Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-Thymidine. Blood 58(3): 471-476, 1981.

  17. Durie BGM, SalmonSE: The current status and future prospects of treatment for multiple myeloma. Clinic in Haematology 11:181-210, 1982.

  18. Durie BGM, Persky B, Soehnlen BJ, Grogan TM, Salmon SE: Amyloidproduction in human myeloma stem cell culture with morphologic evidence ofamyloid secretion by associated macrophages.N Engl J Med307:1689-1692, 1982.

  19. Durie BGM, Young LA, Simon SE: Human myeloma in vitro colonygrowth:Interrelationships between drug sensitivity, cell kinetics, andpatient survival duration. Blood61:929-934, 1983.

  20. Salmon SE, Haut A, Bonnet JD, et al. Alternating combination chemotherapy and levamisole improves survival of multiple myeloma: A Southwest Oncology Group study. J Clin Oncol1(8): 453-461, 1983.

  21. Durie BGM: Ismyeloma really a monoclonal disease? Br J Haematol57 (3):357-363, 1984.

  22. Boccadoro M, Gavarotti P, Fossati G, Pileri A, Marmont F, Neretto G, Gallamini A, Volta C, Trinalto M, Testa MG, Amadori S, Mandelli F, Durie BGM: Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS) smoldering myeloma and remission phase myeloma: A reliable indicator of patients not requiring therapy. Br JHaematol 58:689-696, 1984.

  23. Durie BGM, Vela E, Baum V, Leibovitz A, Payne CM, Richter LC, Grogan TM, Trent JM: Establishment of two new myeloma cell lines from bilateral pleural effusions:Evidence for sequential in vivo clonal change. Blood 66:548-555, 1985.

  24. Durie BGM, Grogan TM: CALLA-positive myeloma: An aggressive subtype with poor survival. Blood 66:229-232, 1985.

  25. Bataille R, Durie BGM, Grenier J, Sany J: Prognostic factors and staging inmultiple myeloma: A reappraisal. J Clin Oncol, 4:80-87, 1986.

  26. Durie BGM, Dixon B, Carter S, Stephens R, Bonnet J, Morrison F, Costanzi J, Salmon SE: Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol, 4:1127-1237, 1986.

  27. Durie BGM, Clouse L, Baraich T, et al. Interferon alfa-2b-cyclophosphamide combination studies: Invitro and phase I-II clinical results. Seminars in Oncol, 8(S2):84-88, 1986.

  28. Durie BGM. Stagingand kinetics of multiple myeloma. Seminars in Oncol, 13(3):300-309, 1986.

  29. Garrett I, Durie BGM, Nedwin G, Gillespie A, Bringman T, Sabatin iM, Bertolini D, Mundy G: Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. New Engl J Med, 317:526-532, 1987.

  30. Durie BGM, Dalton WS: Reversal of drug-resistance in multiple myeloma with verapamil. Brit J Haemat, 68:203-206, 1988.

  31. Buzaid A, Durie BGM: Management of Refractory Myeloma: A Review. J Clin Onc. 6(5): 889-905, 1988.

  32. Rossi J-F, Durie BGM, Duperray C, et al: Phenotypic and functional analysis of 1, 25 dihydroxyvitaminD3 receptor mediated modulation of the human myeloma cell line RPMI8226. Cancer Research, 48:1213-1216, 1988.

  33. Danel L, Vincent C, Rousset F, et al: Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. J. Steroid Biochem, 30(1-6):363-367, 1988.

  34. Durie BGM, Grogan TM, Spier C, Vela E, Baum V, Rodriquez MA, Frutiger Y: Myelomonocytic myeloma cell line (LB84-1). Blood, Vol 73, No 3, Feb 151989(p770-776).

  35. Durie BGM, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman C: Prognostic value of pretreatment serum ß2 microglobulin in myeloma: A Southwest Oncology Group Study. Blood, 75:823-830, 1990.

  36. Van Camp B, Durie BGM, SpierC, DeWaele M, Van RietI, Vela E, Frutiger Y, Richter L, Grogan T: Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1;Leu-19). Blood, 76:377-382, 1990.

  37. Durie BGM, Crowley J, Coltman CA, et al: Phase II evaluation of bisantrene in refractory multiple myeloma: a Southwest Oncology Group Study. Investigational New Drugs, 9:329-331, 1991.

  38. Durie BGM: Cellularand molecular genetic features of myeloma and related disorders. Hematology/OncologyClinics of North America, 6(2):463-477, 1992.

  39. SonneveldP, Durie BGM, Lokhorst HM, Frutiger Y, Schoester M, Vela EE: Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Brit J Haematol, 83:63-67, 1993.

  40. Durie B, Urnovitz J. Cell and molecular biology of simian virus 40: Implications for human infections and disease. J Nat Ca Instut. 91(13):1166-1167, 1999.

  41. Durie BGM, Urnovitz HB, Murphy WH: RT-PCR amplicons (RNA) in the plasma of multiple myeloma patients, clinical relevance and molecular pathology. Acta Oncologica.39 (No.7): 789-796, 2000.

  42. Durie BGM, Stepan DE: Efficacy of low dose thalidomide in multiple myeloma. Elec J Onc, 2000, 1, 1-8.Available at www.Elecjoncol.org/ejo/cgi-bin/Escripts2000.pl

  43. Durie BGM: The epidemiology of multiple myeloma. Seminars in Hematology, Vol 38, No 2, Suppl 3: 1-5, 2001.

  44. Durie BGM: Low-dose thalidomide in myeloma: efficacy and biologic significance. Seminars inOncology, 29 (No 6, Suppl 17): 34-38, 2002.

  45. Durie BGM, Waxman AD, D’Agnolo A, et al. Whole body F-FDG PET identifies high-risk myeloma. J NuclMed, 43:1457-1463, 2002.

  46. Kumar A, Loughran T, Alsina M, et al: Management of multiple myeloma: A systemic review and critical appraisal of published studies. The Lancet-Oncology; 4:293-304, 2003.

  47. IMWG. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br JHaematol, 121: 749-757, 2003.

  48. Durie BGM, Jacobson J, Barlogie B, et al. Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in SWOG chemotherapy trials. J Clin Onc, 22: 1857-1963, 2004.

  49. Durie BGM. New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals. Clin Lymphoma Myeloma, 6 (3): 181-90, 2005.

  50. Durie BGM, Katz M, McCoy J, et al: Osteonecrosis of the jaw and bisphosphonates. New Eng. J. Med, Jul 7, 353(1): 99-102, 2005.

  51. Durie BGM, Harousseau JL, et al. International uniform response criteria for multiple myeloma. Leukemia, 20:1467-1473, 2006.

  52. Durie BG, Attal M, Beksac M, et al. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proceedings, 82:516-522, 2007.

  53. Ludwig H, Durie BGM, Bolejack V: Myeloma in patients younger than age 50 years with more favorable features and shows better survival: An analysis of 10, 549 patients from the International Myeloma Working Group. Blood; 111(8):4039-4047, 2008.

  54. Hussein MA, Vrionis FD, Allison R, et al: The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group consensus statement. Leukemia;22:1479-1484, 2008.

  55. Durie BGM.(Editorial) Treatment of myeloma- Are we making progress?. New Engl J Med;359(9):964-966, 2008.

  56. Durie BGM.(Commentary) Crossover confusion: MPT still best. Blood; 112(8): 2998-2999, 2008.

  57. Durie BGM.(Commentary - 25th Year Anniversary Issue) Myeloma therapy: 25 years forward- Immune modulation then and now. J Clin Oncol; 26(29):1-3, 2008.

 related articles